Gary P. O’Neill - Concepedia

Author

Gary P. O’Neill

Also Known As

G O'Neill, G O’Neill, G P O'Neill, G. O'NEILL, G. O'Neill, G. O’Neill, G. P. O'NEILL, G. P. O'Neill, G. P. O’neill, G.P O'Neill

107

Publications

11.2K

Citations

H-Index

124

Concepts

All Affiliations

Merck Canada Inc. (Canada)Merck & Co., Inc., Rahway, NJ, USA (United States)TransCanada (Canada)United States Military Academy Yale University

About

Gary P. O’Neill is an author at Merck Canada Inc. (Canada) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	47	7.9K
2	Engineering	2	2	104
3	Education	1	1	22
4	Health Sciences	1	1	91
5	Language Studies	1	1	22

Gary P. O’Neill

Publications

11.1K

Citations

H-Index

Page 1

	Year	Citations
Characterization of the human cysteinyl leukotriene CysLT1 receptor Kevin R. Lynch, Gary P. O’Neill, Qingyun Liu, Nature InflammationCytokineG Protein-coupled ReceptorMedicineImmunology	1999	967
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Stacia Kargman, Gary P. O’Neill, Philip J. Vickers, PubMed Chemoprevention StrategyImmunologyPathologyCancer BiologyTumor Biology	1995	836
Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissues Gary P. O’Neill, Anthony W. Ford‐Hutchinson FEBS Letters Lipid PeroxidationPathologyCox MrnasOxidative StressInflammation	1993	711
Characterization of the Human Cysteinyl Leukotriene 2 Receptor Christopher E. Heise, Brian F. O’Dowd, David J. Figueroa, Journal of Biological Chemistry InflammationSignal TransductionG Protein-coupled ReceptorMedicineFunctional Selectivity	2000	660
Discovery of a receptor related to the galanin receptors Dennis K Lee, Tuan Nguyen, Gary P. O’Neill, FEBS Letters Pcr SearchSignal TransductionBrain RegionsBiochemistryFunctional Selectivity	1999	498
Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts Stacia Kargman, S. Charleson, Mark E. Cartwright, Gastroenterology Animal PhysiologyNeuropeptidesBiochemistryGastrointestinal PharmacologyHuman Gastrointestinal Tracts	1996	465
The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor Petpiboon Prasit, Z Wang, Christine Brideau, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryActive Cyclooxygenase-2 InhibitorPharmaceutical ScienceBiochemistry	1999	426
Receptor for Motilin Identified in the Human Gastrointestinal System Scott D. Feighner, Carina P. Tan, Karen K. McKee, Science Signal TransductionBiochemistryMotilin IdentifiedMedicineG Protein-coupled Receptor	1999	403
Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles Chi‐Chung Chan, S. Boyce, Christine Brideau, Journal of Pharmacology and Experimental Therapeutics	1999	397
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor Denis Riendeau, M. David Percival, S. Boyce, British Journal of Pharmacology Pge2 ProductionChemoprevention StrategyImmunologyPharmacotherapyPharmaceutical Chemistry	1997	326

Page 1